Show simple item record

dc.contributor.authorLedermann, J
dc.contributor.authorOza, A
dc.contributor.authorLorusso, D
dc.contributor.authorAghajanian, C
dc.contributor.authorOaknin, A
dc.contributor.authorDean, A
dc.contributor.authorColombo, N
dc.contributor.authorWeberpals, J
dc.contributor.authorClamp, Andrew R
dc.contributor.authorScambia, G
dc.contributor.authorLeary, A
dc.contributor.authorHolloway, R
dc.contributor.authorO'Malley, D
dc.contributor.authorCameron, T
dc.contributor.authorMaloney, L
dc.contributor.authorGoble, S
dc.contributor.authorLin, K
dc.contributor.authorSun, J
dc.contributor.authorGiordano, H
dc.contributor.authorColeman, R
dc.date.accessioned2017-11-23T21:40:56Z
dc.date.available2017-11-23T21:40:56Z
dc.date.issued2017-09
dc.identifier.citationLBA40_PR ARIEL3: a phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC). 2017, 28(suppl_5): Ann Oncolen
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.doi10.1093/annonc/mdx440.034
dc.identifier.urihttp://hdl.handle.net/10541/620700
dc.language.isoenen
dc.relation.urlhttp://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx440.034/4109946/LBA40PRARIEL3-A-phase-3-randomised-doubleblinden
dc.rightsArchived with thanks to Annals of Oncologyen
dc.titleLBA40_PR ARIEL3: a phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC).en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentGynaecological Oncology, University College London Cancer Institute and UCL Hospitals, Londonen
dc.identifier.journalAnnals of Oncologyen


This item appears in the following Collection(s)

Show simple item record